A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter

Abstract

In support of this, Aβ oligomer reduction in an AD mouse model leads to memory preservation [2, 3], and clinical benefit was in trials of lecanemab, which targets Aβ oligomers and protofibrils [4], in AD patients, encouraging the continued development of Aβ oligomer-targeting therapies. Given the semi-quantitative nature of the Aβ oligomer assays, the percent change of Aβ oligomer level relative to baseline (average of the pre-dose values) was calculated for each patient (Fig. 1b–g). Lizama BN, Kahle J, Catalano SM, Caggiano AO, Grundman M, Hamby ME. Sigma-2 receptors—from basic biology to therapeutic target: a focus on age-related degenerative diseases.